Novara BioSystems

Novara BioSystems is a Milan-based biotech-AI corporation operating from a renovated industrial complex in the Bicocca district that was, until twenty years ago, a working tire factory. Three hundred staff, a research division that runs joint projects with several Italian university hospitals, and a corporate aesthetic that the firm’s design team has described internally as “Lombardian institutional modernism,” which means glass, steel, and the occasional disconcerting piece of contemporary art in unexpected corridors.

Their products are mid-corporate health AI — diagnostic-imaging support, surgical-planning models, the kind of high-six-figure Cu engagements that involve clinical evaluation studies and journal publication in their post-deployment phase. The firm has a particular reputation for image-classification work in the kinds of clinical contexts where the imaging hardware is older and the disease prevalence is higher than the foreign vendors’ training data assumes.

The CEO is a former oncology research director who left academic medicine after, in his words, “deciding the bottleneck was no longer the science.” He still publishes occasionally. His staff have stopped asking him to slow down.

Novara BioSystems maintains a confidential internal review process for every model the firm declines to deploy — the rejected commissions, the abandoned prototypes, the projects that were scientifically interesting but ethically uncomfortable. The review process documents what the model could have done and what made the firm unwilling to deliver it. The documentation is not shared with prospective clients. It is, however, read at length by every new senior engineer during their first year, as part of what the CEO calls “professional formation.” He considers this more important than any other onboarding component.